Hydrogen sulfide inhibits inflammatory pain and enhances the analgesic properties of delta opioid receptors
Porta, Aina (Universitat Autònoma de Barcelona. Institut de Neurociències)
Rodríguez, Laura (Universitat Autònoma de Barcelona. Institut de Neurociències)
Bai, Xue (Universitat Autònoma de Barcelona. Institut de Neurociències)
Batallé Melgarejo, Gerard (Universitat Autònoma de Barcelona. Institut de Neurociències)
Roch, Gerard (Universitat Autònoma de Barcelona. Institut de Neurociències)
Pouso-Vázquez, Enric (Universitat Autònoma de Barcelona. Institut de Neurociències)
Balboni, Gianfranco (University of Cagliari. Department of Life and Environmental Sciences)
Pol, Olga (Universitat Autònoma de Barcelona. Institut de Neurociències)

Fecha:	2021
Resumen:	Chronic inflammatory pain is present in many pathologies and diminishes the patient's quality of life. Moreover, most current treatments have a low efficacy and significant side effects. Recent studies demonstrate the analgesic properties of slow-releasing hydrogen sulfide (HS) donors in animals with osteoarthritis or neuropathic pain, but their effects in inflammatory pain and related pathways are not completely understood. Several treatments potentiate the analgesic actions of δ-opioid receptor (DOR) agonists, but the role of HS in modulating their effects and expression during inflammatory pain remains untested. In C57BL/6J male mice with inflammatory pain provoked by subplantar injection of complete Freund's adjuvant, we evaluated: (1) the antiallodynic and antihyperalgesic effects of different doses of two slow-releasing HS donors, i. e. , diallyl disulfide (DADS) and phenyl isothiocyanate (P-ITC) and their mechanism of action; (2) the pain-relieving effects of DOR agonists co-administered with HS donors; (3) the effects of DADS and P-ITC on the oxidative stress and molecular changes caused by peripheral inflammation. Results demonstrate that both HS donors inhibited allodynia and hyperalgesia in a dose-dependent manner, potentiated the analgesic effects and expression of DOR, activated the antioxidant system, and reduced the nociceptive and apoptotic pathways. The data further demonstrate the possible participation of potassium channels and the Nrf2 transcription factor signaling pathway in the pain-relieving activities of DADS and P-ITC. This study suggests that the systemic administration of DADS and P-ITC and local application of DOR agonists in combination with slow-releasing HS donors are two new strategies for the treatment of inflammatory pain.
Ayudas:	Instituto de Salud Carlos III PI1800645
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Analgesia ; Antioxidants ; Delta opioid receptors ; Inflammation ; Oxidative stress ; Pain
Publicado en:	Antioxidants, Vol. 10 Núm. 12 (december 2021) , p. 1977, ISSN 2076-3921

DOI: 10.3390/antiox10121977
PMID: 34943080

21 p, 3.3 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados